A Phase 1 interventional study of [68Ga]Ga-OncoACP3 in Prostate Cancer, Prostate Cancer Metastatic Disease and PSA Level Greater Than 0.2, sponsored by Philogen S.p.A.. Completed at 3 sites in Italy. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-06.
Sponsored by Philogen S.p.A. · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing Gallium-68 in Prostatic Neoplasms — 8 open to participants now, 8 under way, 2 of them phase 3. Gallium-68 · Prostatic Neoplasms.
Among the 11 studies testing Gallium-68 in Prostatic Neoplasms, this one is the 9th largest by enrollment, is the only one that started in 2025, is one of 6 in phase 1, and was the 4th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →8 of the 11 studies testing Gallium-68 in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Lantheus Medical Imaging · Sites in United States
Ages 18+ · Men only
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–80 · Men only
Integrated Haematology and Oncology Network · Sites in Australia
Ages 18+
RenJi Hospital · Sites in China
Ages 18–75
Anhui Provincial Hospital · Sites in China
Ages 18–90 · Men only · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 5 · Phase 3 2
First in 2018; this study’s year is marked. 1 started in 2025.
This study's enrollment of 20 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 40 across the 11 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 11 have an industry lead sponsor. The 9 most frequent:
Philogen S.p.A. is the lead sponsor of 49 studies on the registry; 16 are open to participants now.
Philogen S.p.A. has 2 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing Gallium-68 in Prostatic Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07689656Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA Clinical Study of [68Ga]Ga-ELI421 Injection PET Imaging in Patients With Prostate Cancer | 2026-12-30 |
| NCT07781852Lumina Pharmaceuticals IncEvaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing Gallium-68 in Prostatic Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to assess the safety and dosimetry of [68Ga]Ga-OncoACP3 in patients with prostate cancer.
The Acid Phosphatase 3 (ACP3) is expressed in primary and metastatic prostate cancer lesions. OncoACP3 is a new ligand for ACP3.
This is a phase I, multicenter clinical trial to evaluate the safety, dosimetry and biodistribution of [68Ga]Ga-OncoACP3 as a PET radiotracer for the diagnostic imaging of prostate cancer. In this trial, 68Ga-OncoACP3 is offered to prostate cancer patients who already received standard of care imaging and might therefore complement available modalities.
Eligible patients for this trial are prostate cancer patients, aged 18 years or more with:
All patients will undergo PET/CT imaging with [68Ga]Ga-OncoACP3.
Patients are divided into two cohorts:
Both cohorts are recruited in parallel, and patients are assigned to the respective cohort based on their disease extent. Whenever possible, patients are enrolled in cohort A, unless they are unsuitable for cohort A, or the required number of patients has already been enrolled in cohort A.
All patients will receive a single intravenous bolus administration of [68Ga]Ga-OncoACP3 and biodistribution, PK, and dosimetry of [68Ga]Ga-OncoACP3 will be assessed based on a series of PET/CT scans, blood and urine sampling.
Full dosimetry evaluations will be performed for all patients in cohort A. Dosimetry in the other patients may be performed to the extent that it is possible based on their disease burden (i.e., only organs not affected by malignant lesions can be evaluated), as appropriate.
All patients will be assessed for safety. In addition, relative uptake to appropriate reference tissue of [68Ga]Ga-OncoACP3 as well as semiquantitative parameters such as SUVmax/SUVmean/SUVsd, are determined. The correlation of [68Ga]Ga-OncoACP3 uptake with immunopathology staining for ACP3 will be evaluated in patients undergoing surgery or tumor biopsy collection. For patients who undergo PSMA-PET/CT within 4 weeks before or after the [68Ga]Ga-OncoACP3-PET/CT scan, the lesion detection rate will be compared Full dosimetry evaluations will be performed for all patients in cohort A. Additional dosimetry in the other patients may be performed to the extent that it is possible based on their disease burden (i.e., only organs not affected by malignant lesions can be evaluated).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Prostate cancer patients with:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
5 male patients without visceral or bone metastases, which would interfere with dosimetry evaluation of healthy organs.
All patients who meet the eligibility criteria (up to 15 patients)
Drug: [68Ga]Ga-OncoACP3
Single intravenous bolus injection.
Cohort A: Dosimetry - Effective dose equivalent (mSv)
Whole-body effective dose (mSv) following administration of a single dose of \[68Ga\]Ga-OncoACP3.
Time frame: Assessed on day 1
Cohort A: Dosimetry - Effective dose absorbed doses (mGy)
Absorbed doses (mGy) of normal organs following administration of a single dose of \[68Ga\]Ga-OncoACP3.
Time frame: Assessed on day 1
All patients: Safety (AEs and SAEs)
Safety of administration of \[68Ga\]Ga-OncoACP3, assessed based on Common Toxicity Criteria (CTCAE version 5.0)
Time frame: Throughout study, until a maximum of 7 days after the administration of the study drug.
Pharmacokinetics (PK) - Blood
Pharmacokinetics (PK) of \[68Ga\]Ga-OncoACP3 based on measurement on blood of residual radioactivity over time \[kBq/mL\]
Time frame: Assessed on day 1
Excretion - Urine
Excretion of \[68Ga\]Ga-OncoACP3 based on measurement of residual radioactivity in the urine over time \[kBq\]
Time frame: Assessed on day 1
Biodistribution profile: SUVmax
Uptake of \[68Ga\]Ga-OncoACP3 in tumor lesions and healthy organs in terms of SUVmax
Time frame: Assessed on day 1
Biodistribution profile: SUVmean
Uptake of \[68Ga\]Ga-OncoACP3 in tumor lesions and healthy organs in terms of SUVmean
Time frame: Assessed on day 1
Biodistribution profile: SUVsd
Uptake of \[68Ga\]Ga-OncoACP3 in tumor lesions and healthy organs in terms of SUVsd
Time frame: Assessed on day 1
Immunopathology staining
Correlation of the uptake of \[68Ga\]Ga-OncoACP3 with immunopathology staining for ACP3 expression and comparison to staining for PSMA expression, in all patients for whom surgical or biopsy specimen are available.
Time frame: Within 8 weeks of the scan, surgery and biopsy collection
Lesion detection rate
Lesion detection rate compared to PSMA-PET/CT.
Time frame: The [68Ga]Ga-OncoACP3-PET/CT scan needs to be collected within 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Oct 2025, 5 months.
Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 5 months is below that.
Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gallium-68